# Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

> **NCT01475370** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** OCV-501

## Key facts

- **NCT ID:** NCT01475370
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-24
- **Primary completion:** 2016-12-22
- **Final completion:** 2016-12-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475370, "Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01475370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*